A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment
The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
Review of serious adverse events linked with GLP-1 agonists in T2D and obesity treatment. Evidence remains mixed on risks of pancreatitis, thyroid cancer, and other serious AEs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A non-systematic review by Tobaiqy et al., 2024 [128] did not allow the authors to draw any firm conclusions, given the mixed results of the included trials.”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [128]
In the citing paper
“A number of reviews on similar topics have also been previously published [124-128], focusing on efficacy [125] or case reports [126], being narrative reviews [127,128], or including a much smaller sample of studies [124].”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [128]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 6×
“[ 3].”
InfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Adverse drug reactions: definitions, diagnosis, and management
Edwards, I. R., & Aronson, J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02799-9 · Cited by 2,979
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 1×
“In contrast, others find no signifi - cant association [ 9, 10].”
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“…patients with heart failure with preserved ejection fraction (HFpEF) and obe - sity treated with semaglutide (2.4 mg) experienced more significant reductions in symptoms and physical limita - tions, improved exercise function, and more significant weight loss than those receiving a placebo [ 30 ].”
InfluentialPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“Patients are advised against discontinuing GLP agonists without medical consultation, and healthcare professionals should monitor for mood changes [ 45].”
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672 · cited 2×
“Animal studies have fueled anxieties, demonstrating that GLP-1 agonists promote thyroid C-cell proliferation and hyperplasia in rodents, potentially leading to increased calcitonin production [ 18].”
Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592 · cited 5×
“For example, such treatment could lead to increased heart rate and reduced left ventricular ejection fraction (LVEF) associated with liraglutide [ 5].”
InfluentialHersh, W. R., Weiner, M. G., Embi, P. J., Logan, J. R., Payne, P. R. O., Bernstam, E. V., Lehmann, H. P., Hripcsak, G., Hartzog, T. H., Cimino, J. J., et al. (2013) · Medical Care · doi:10.1097/mlr.0b013e31829b1dbd · Cited by 567 · cited 1×
“Adverse events are often considered secondary objectives, leading to less thorough reporting [ 55 ].”
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023) · JAMA · doi:10.1001/jama.2023.19574 · Cited by 471
Pirmohamed, M., Breckenridge, A. M., Kitteringham, N. R., & Park, B. K. (1998) · BMJ · doi:10.1136/bmj.316.7140.1295 · Cited by 454
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358 · cited 3×
“Close monitoring and discontinuation of medication may be necessary in cases of acute worsening of kidney function [ 35, 36].”
He, L., Wang, J., Ping, F., Yang, N., Huang, J., Li, Y., Xu, L., Li, W., & Zhang, H. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0338 · Cited by 356
Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-01707-4 · Cited by 346 · cited 1×
“At the same time, liraglutide also decreased the occurrence of similar outcomes in this population [ 3, 27, 28].”
Clarification of Terminology in Drug Safety
Aronson, J. K., & Ferner, R. E. (2005) · Drug Safety · doi:10.2165/00002018-200528100-00003 · Cited by 328
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320 · cited 2×
“[ 22].”
InfluentialEffects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Association of semaglutide with risk of suicidal ideation in a real-world cohort
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Nature Medicine · doi:10.1038/s41591-023-02672-2 · Cited by 248 · cited 3×
“[ 10].”
Adverse Events in Randomized Trials: Neglected, Restricted, Distorted, and Silenced
Ioannidis, J. P. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.313 · Cited by 243
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
Shetty, R., Basheer, F. T., Poojari, P. G., Thunga, G., Chandran, V. P., & Acharya, L. D. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102427 · Cited by 145
Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139 · cited 2×
“None of the cardiovascular outcomes trials (CVOTs) reported fatal heart failure events or outpatient heart failure exacerbations, except for the REWIND trial [ 32, 33 ], which documented urgent heart failure visits without any significant differences between the treatment and control groups [ 33 ].”
Reporting of adverse drug reactions in randomised controlled trials – a systematic survey
Loke, Y. K., & Derry, S. (2001) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-1-3 · Cited by 138
Faillie, J.-L., Yu, O. H., Yin, H., Hillaire-Buys, D., Barkun, A., & Azoulay, L. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.1531 · Cited by 134
Serious adverse events in academic critical care research
Cook, D., Lauzier, F., da Rocha, M. G., Sayles, M., & Finfer, S. R. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071366 · Cited by 127
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127 · cited 2×
“[ 23].”
Cao, C., Yang, S., & Zhou, Z. (2020) · Endocrine · doi:10.1007/s12020-020-02223-6 · Cited by 124
Tobaiqy, M. A., Elkout, H., & MacLure, K. (2021) · Vaccines · doi:10.3390/vaccines9040393 · Cited by 119
Self-citationHeuvelman, V. D., Van Raalte, D. H., & Smits, M. M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz323 · Cited by 106
Neves, J. S., Packer, M., & Ferreira, J. P. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.03.017 · Cited by 106
Tobaiqy, M., & Elkout, H. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01694-7 · Cited by 88
Self-citationPinto, L. C., Falcetta, M. R., Rados, D. V., Leitão, C. B., & Gross, J. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-38956-2 · Cited by 84
Challenges in Coding Adverse Events in Clinical Trials: A Systematic Review
Schroll, J. B., Maund, E., & Gøtzsche, P. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041174 · Cited by 70
Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes
Faillie, J., Yin, H., Yu, O. H. Y., Herrero, A., Altwegg, R., Renoux, C., & Azoulay, L. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2430 · Cited by 67 · cited 6×
“Observational studies hint at potential associations, prompting further investigation, especially regarding individual susceptibility due to pre-existing bowel conditions or elec - trolyte imbalances [ 6, 42, 43].”
InfluentialBea, S., Son, H., Bae, J. H., Cho, S. W., Shin, J., & Cho, Y. M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15292 · Cited by 64 · cited 2×
“Subgroup analyses and sensitivity analyses supported these findings [ 11].”
Rehfeld, J. F., Knop, F. K., Asmar, A., Madsbad, S., Holst, J. J., & Asmar, M. (2018) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2018.1530297 · Cited by 62 · cited 2×
“Furthermore, substantial weight loss in some patients using GLP-1 agonists may contribute to an increased risk of gallbladder disorders [ 37, 38].”
On-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice
Rosol, T. J. (2013) · Toxicologic Pathology · doi:10.1177/0192623312472402 · Cited by 61
Acute Pancreatitis Associated with Liraglutide
Lee, P. H., Stockton, M. D., & Franks, A. S. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p714 · Cited by 57
Nexøe‐Larsen, C. C., Sørensen, P. H., Hausner, H., Agersnap, M., Baekdal, M., Brønden, A., Gustafsson, L. N., Sonne, D. P., Vedtofte, L., Vilsbøll, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13420 · Cited by 51 · cited 3×
“…events occur during the dose-escalation phase; patients experiencing GIT adverse events when advancing to a higher dose should revert to the lower dose for a few days before gradually increasing it; treatment may be temporarily withheld until the resolution of adverse events before resuming [ 36].”
Acute Kidney Injury Associated With Semaglutide
Leehey, D. J., Rahman, M. A., Borys, E., Picken, M. M., & Clise, C. E. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2020.10.008 · Cited by 51
Putting GLP-1 RAs and Thyroid Cancer in Context: Additional Evidence and Remaining Doubts
Thompson, C. A., & Stürmer, T. (2023) · Diabetes Care · doi:10.2337/dci22-0052 · Cited by 51 · cited 3×
“These findings can inform clinicians when address - ing patient concerns about a potential but unproven link between GLP-1 agonist therapy and thyroid cancer [ 20, 21].”
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
Mondragon, A., Davidsson, D., Kyriakoudi, S., Bertling, A., Gomes-Faria, R., Cohen, P., Rothery, S., Chabosseau, P., Rutter, G. A., & da Silva Xavier, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104873 · Cited by 37
A potentially serious adverse effect of GLP-1 receptor agonists
Lu, J., Liu, H., Zhou, Q., Wang, M., & Li, Z. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.020 · Cited by 34
Pradhan, R., Patorno, E., Tesfaye, H., Schneeweiss, S., Yin, H., Franklin, J., Pawar, A., Santella, C., Yu, O. H. Y., Renoux, C., et al. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac021 · Cited by 30
Exenatide-Induced Chronic Damage of Pancreatic Tissue in Rats
Yu, X., Tang, H., Huang, L., Yang, Y., Tian, B., & Yu, C. (2012) · Pancreas · doi:10.1097/mpa.0b013e31824e67a3 · Cited by 28
Funch, D., Mortimer, K., Ziyadeh, N. J., Seeger, J. D., Zhou, L., Ng, E., Ross, D., Major-Pedersen, A., Bosch-Traberg, H., Gydesen, H., et al. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s305496 · Cited by 24 · cited 2×
“However, caution is warranted due to poten - tial residual confounding and surveillance bias, highlighting the need for further investigation into the association between liraglutide use and thyroid cancer risk [ 24].”
A case report of allergy to exenatide
Perez-Rodriguez, E., Martínez-Tadeo, J. A., Callero, A., Hernández, G., Rodriguez‐Plata, E., & García-Robaina, J. C. (2014) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2014.05.011 · Cited by 18
Delayed Hypersensitivity Reaction to Liraglutide: A Case Report
Carvallo, A., Silva, C., Gastaminza, G., & D’Amelio, C. (2020) · Journal of Investigational Allergology and Clinical Immunology · doi:10.18176/jiaci.0521 · Cited by 16
Systemic Allergic Reaction to the GLP-1 Receptor Agonist Exenatide
Steveling, E., Winzeler, B., & Bircher, A. (2014) · Journal of Pharmacy Technology · doi:10.1177/8755122514539462 · Cited by 14
Bianchi, L., Marash, S. A. B., Malatesta, N., Hansel, K., Tramontana, M., & Stingeni, L. (2023) · JEADV Clinical Practice · doi:10.1002/jvc2.255 · Cited by 3
No causal link between GLP-1 RAs and suicidal ideation
(2024) · Reactions Weekly · doi:10.1007/s40278-024-52517-9 · Cited by 1
Cited by
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 57
“These effects are closely related to the activation of GLP-1 receptors in both central and peripheral pathways, often leading to reduced treatment adherence or even discontinuation, which can compromise therapeutic outcomes (Tobaiqy, 2024).”
Georgianos, P. I., Vaios, V., Koufakis, T., & Liakopoulos, V. (2024) · Drugs · doi:10.1007/s40265-024-02091-8 · Cited by 27
“Other commonly reported side effects are hypoglycemia (mainly in patients receiving combination therapy with insulin), tachycardia, gallbladder disease, pancreatitis, and retinopathy [41].”
Tian, Q., Song, Y., Deng, Y., & Lin, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1593134 · Cited by 26
“These fi ndings are consistent with reports on other GLP-1 receptor agonists, including semaglutide and liraglutide, which also demonstrate a high prevalence of nausea and vomiting as common treatment-related side effects (40, 41).”
Scheen, A. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16453 · Cited by 25
Zhao, X., Liu, Y., Wang, D., Li, T., Xu, Z., Li, Z., Bai, X., & Wang, Y.-C. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5515 · Cited by 12
“…with GLP‑1RAs, among which gastrointestinal diseases (commonly nausea, diarrhea, vomiting and constipation) are the most frequently reported; however, most gastrointestinal events are of mild to moderate severity, transient and do not require permanent discontinuation of treatment (179,180).”
Metadata
- Authors
- Tobaiqy, M.
- Affiliations
- University of Jeddah (SA)
- Corresponding author
- Tobaiqy, Mansour
- ORCID
- Tobaiqy, Mansour
- Venue
- Pharmacological Reports
- Published
- 2024-08-02
- Volume
- 76
- Issue
- 5
- Pages
- 981-990
- ISSN
- 1734-1140 (ISSN-L)
- 2299-5684
- OpenAlex
- W4401252114
- Semantic Scholar
- e8ec052a486a6c62e54e2ef0c69912aff2356f33
- Cited by
- 25
- References
- 58
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmacological Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- GLP-1 receptor agonists, serious adverse events, drug safety, type 2 diabetes, obesity treatment, anaphylaxis, cardiovascular adverse events, gastrointestinal adverse effects, psychiatric adverse events
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.